Card paper
КОМБІНОВАНА ТЕРАПІЯ
ibliography
Патент України (на 20 р.)
(51)
IPC
A61K 45/06 (2006.01)
A61K 31/4184 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/4745 (2006.01)
A61K 31/496 (2006.01)
A61K 31/506 (2006.01)
A61K 31/519 (2006.01)
A61K 31/53 (2006.01)
A61K 31/5377 (2006.01)
A61P 35/00 (2006.01)
A61K 45/06 (2006.01)
A61K 31/4184 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/4745 (2006.01)
A61K 31/496 (2006.01)
A61K 31/506 (2006.01)
A61K 31/519 (2006.01)
A61K 31/53 (2006.01)
A61K 31/5377 (2006.01)
A61P 35/00 (2006.01)
(11)
118846
(22)
19.03.2014
(24)
25.03.2019
(21)
a201510275
(31)
61/804,056
(32)
21.03.2013
(33)
US
(41)
12.01.2016, бюл. № 1
(46)
25.03.2019, бюл. № 6
(56)
WO2012095505, A1, 19.07.2012
WO2012068468, A1, 24.05.2012
WO03077914, A1, 25.09.2003
WO2006053201, A2, 18.05.2006
EP2570127, A1, 20.03.2013
WO2012178038, A1, 27.12.2012
WO2009143211, A2, 26.11.2009
FLAHERTY KEITH T ET AL, "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations", NEW ENGLAND JOURNAL OF MEDICINE, (201211), vol. 367, no. 18, ISSN 0028-4793, pages 1694 - 1703, XP002725869 [Y] 1-3,15 * the whole document *
SU FEI ET AL, "Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation", CANCER RESEARCH, (201202), vol. 72, no. 4, ISSN 0008-5472, pages 969 - 978, XP002725870 [Y] 1-3,15 * the whole document, in particular page 974, column 2 *
K S M SMALLEY ET AL, "Integrating BRAF/MEK inhibitors into combination therapy for melanoma", BRITISH JOURNAL OF CANCER, (20090120), vol. 100, no. 3, doi:10.1038/sj.bjc.6604891, ISSN 0007-0920, pages 431 - 435, XP055123646 [Y] 1-3,15 * the whole document, in particular the chapter "Conclusion" *
JACK MCCAIN, "The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.", P&T, (201302), vol. 38, no. 2, ISSN 1052-1372, pages 96 - 108, XP055093262 [Y] 1-3,15 * the whole document, in particular page 105, column 2, chapter "Combination Therapy" and chapter "Conclusion" *
RYAN J. SULLIVAN ET AL, "Resistance to BRAF-targeted therapy in melanoma", EUROPEAN JOURNAL OF CANCER, (20130102), vol. 49, no. 6, doi:10.1016/j.ejca.2012.11.019, ISSN 0959-8049, pages 1297 - 1304, XP055082343 [Y] 1-3,8-12,15 * the whole document, in particular page 1299, column 2, first paragraph *
SIMON GIROUX, "Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (201301), vol. 23, no. 2, doi:10.1016/j.bmcl.2012.11.037, ISSN 0960-894X, pages 394 - 401, XP055123645 [Y] 1-3,15 * page 399 *
E. HUILLARD ET AL, "Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20120514), vol. 109, no. 22, doi:10.1073/pnas.1117255109, ISSN 0027-8424, pages 8710 - 8715, XP055080274 [Y] 1,2,4-7,15 * the whole document, in particular page 8712 - page 8714 *
JOCELYN HOLASH, "Preclinical strategies to help better identify responder populations in the clinic", NORCAL SOT FALL SYMPOSIUM: NEW FRONTIERS IN ONCOLOGY DRUG DEVELOPMENT, (20120927), XP055139652 [Y] 1,2,5,8-12,15 * page 8 * * page 17, right figure *
E. VERGANI ET AL, "Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032", NEOPLASIA, (201112), vol. 13, no. 12, doi:10.1593/neo.111102, pages 1132 - 1142, XP055081482 [Y] 1,2,6,9,11,12,15 * page 1136, column 2 - page 1137, column 1 * * figures 5,6 * * page 1141, column 1 *
"2011 International Melanoma Congress", PIGMENT CELL & MELANOMA RESEARCH, (20111010), vol. 24, no. 5, doi:10.1111/j.1755-148X.2011.00909.x, ISSN 1755-1471, pages 990 - 1075, XP055082293 [Y] 1,2,6,9-12,15 * Abstract SMR-P91; page 1049 *
THOMAS METZNER ET AL, "Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition", JOURNAL OF INVESTIGATIVE DERMATOLOGY, (20110714), vol. 131, no. 10, doi:10.1038/jid.2011.177, ISSN 0022-202X, pages 2087 - 2095, XP055141652 [Y] 1,2,7,10-12,15 * the whole document, in particular figures 1, 4 and 6 *
JURGEN WOLF ET AL, "A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors", PROCEEDINGS OF THE103RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; 2012 MAR 31-APR 4; CHICAGO, IL. PHILADELPHIA 
, (20120402), XP055141768 [Y] 10-12,15 * the whole document *
, (20120402), XP055141768 [Y] 10-12,15 * the whole document *(85)
20.10.2015
(86)
PCT/IB2014/059975, 19.03.2014
(71)
НОВАРТІС АГ 
НОВАРТИС АГ
NOVARTIS AG
(72)
Капонігро Джордано 
; Стьюарт Даррін ; де Парсеваль Лор
; Стьюарт Даррін ; де Парсеваль Лор Капонигро Джордано ; Стьюарт Даррин ; дэ Парсэваль Лор
; Стьюарт Даррин ; дэ Парсэваль Лор Caponigro, Giordano ; Stuart, Darrin ; de Parseval, Laure
; Stuart, Darrin ; de Parseval, Laure (73)
НОВАРТІС АГ
НОВАРТИС АГ
NOVARTIS AG
(74)
Мошинська Ніна Миколаївна
(98)
Мошинська Ніна Миколаївна
вул. В'ячеслава Чорновола, 25, офіс 3, м. Київ, 01135
вул. В'ячеслава Чорновола, 25, офіс 3, м. Київ, 01135